A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant(FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluorethylene Graft Material on an End-toSide Femoral or Upper Extremity Vascular Access Arterial Anastomosis. - FS2 in Vascular Surgery

OMRIX biopharmaceuticals Ltd0 个研究点目标入组 147 人开始时间: 2005年5月4日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•1. Male and female patients, 18 years or older, requiring elective, primary or repeat vascular procedures with at least one end-to-side femoral or upper extremity vascular access arterial anastomosis (e.g.femoral-femoral, femoral-popliteal, femoral-tibial, ilio-femoral, aorto-bifemoral, abdominal aortic aneurysm, upper extremity vascular access for dialysis) using PTFE grafts, polypropylene sutures and 1:1 needle-to-thread ratio.
•2. Following initial arterial clamp release, the study surgeon determines that adjunctive measures are needed to obtain haemostasis at the study anastomosis.
•3. Patients must be willing to and capable of participating in the study, and provide written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients are excluded due to the following criteria as these may influence obtaining haemostasis: re-vascularisation using autologous conduits (e.g. saphenous vein) or prosthetic material other than PTFE; Patients with autoimmune immunodeficiency diseases (including known HIV); Patients who are undergoing emergency surgery will be excluded as there would be insufficient time to obtain consent; Patients with any intra-operative findings may preclude conduct of the study procedure; In order to protect vulnerable groups, patients who are current drug or alcohol abusers will be excluded; Patients with known intolerance to heparin, blood products or to one of the components of the study products will be excluded to minimise the risk of allergic reaction; Patients who are unwilling to receive blood products are also excluded as FS2 is produced from human plasma; Patients who have participated in another investigational drug or device research study within 30 days of enrollment will also be excluded; As the safety of the product in human pregnancy has not been established, pregnant patients will be excluded from the study.

发起方